Focused On-demand Library for Disks large homolog 4

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our high-tech, dedicated method is applied to construct targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

P78352

UPID:

DLG4_HUMAN

Alternative names:

Postsynaptic density protein 95; Synapse-associated protein 90

Alternative UPACC:

P78352; B7Z1S1; G5E939; Q92941; Q9UKK8

Background:

Disks large homolog 4 (DLG4), also known as Postsynaptic density protein 95 or Synapse-associated protein 90, is pivotal in synaptogenesis and synaptic plasticity. It facilitates the clustering of essential synaptic proteins, interacts with NMDA receptor subunits and potassium channels, and is crucial for NMDA receptor signaling-mediated synaptic plasticity. DLG4's role extends to regulating the intracellular trafficking of certain proteins and maintaining AMPA-type glutamate receptor activation at synaptic sites.

Therapeutic significance:

DLG4's mutation is linked to Intellectual developmental disorder, autosomal dominant 62, characterized by impaired intellectual development. Understanding DLG4's function could unveil novel therapeutic strategies for treating synaptic disorders and intellectual disabilities.